Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-030-02771-1_8
Reference110 articles.
1. Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS (2013) Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 14:703–710. https://doi.org/10.4161/cbt.25191
2. Andersen NJ, Boguslawski EB, Kuk CY, Chambers CM, Duesbery NS (2015) Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts. Int J Oncol 47:71–80. https://doi.org/10.3892/ijo.2015.2989
3. Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21:2157–2166. https://doi.org/10.1158/1078-0432.CCR-14-2821
4. Atreya CE, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, Jackson McRee A, O’Dwyer PJ, Muro K, Tabernero J, van Geel R, Sidhu R, Greger JG, Rangwala FA, Motw M, Wu Y, Orford KW, Corcoran RB (2015) Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Pathol 33(15_suppl):103. https://doi.org/10.1200/jco.2015.33.15_suppl.103
5. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883. https://doi.org/10.1056/NEJM200412303512724
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-11-22
2. EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells;Frontiers in Immunology;2023-07-20
3. The role of genetic testing in the prognosis and management of solid tumors. A literature review;Revista Romana de Medicina de Laborator;2023-07-01
4. A perfused multi-well bioreactor platform to assess tumor organoid response to a chemotherapeutic gradient;Frontiers in Bioengineering and Biotechnology;2023-05-31
5. Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2022-09-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3